A MULTI-CENTER, OPEN-LABEL, EXPLORATORY STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS ≥1 MONTH TO <18 YEARS WITH EPILEPSY SYNDROMES ASSOCIATED WITH GENERALIZED SEIZURES
Latest Information Update: 12 Sep 2023
At a glance
- Drugs Lacosamide (Primary)
- Indications Absence epilepsy; Generalised epilepsy; Generalised seizures; Myoclonic epilepsies; Partial epilepsies; Tonic-clonic epilepsy
- Focus Therapeutic Use
- Sponsors UCB
- 07 Aug 2023 Results assessing safety, tolerability, pharmacokinetics, and preliminary efficacy of lacosamide (up to 12 mg/kg/day or 600 mg/day) as adjunctive therapy in pediatric patients with epilepsy syndromes associated with generalized seizures published in the Epilepsia
- 24 Apr 2018 Status changed from active, no longer recruiting to completed.
- 06 Nov 2017 Status changed from recruiting to active, no longer recruiting.